← Eichor
Study identifier: NCT06625593 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Condition: Advanced Solid Tumor  ·  Sponsor: BeOne Medicines

PhasePhase 1
Planned participants168
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).

This description comes directly from the study's public registry record.

Talk to the study team

Study Director  ·  1.877.828.5568  ·  clinicaltrials@beonemed.com

Always discuss trial participation with your own doctor first.

Locations (52)

Usc Norris Comprehensive Cancer Center (Nccc)Los Angeles, California, United StatesRecruiting
Yale Cancer CenterNew Haven, Connecticut, United StatesRecruiting
Mayo Clinic RochesterRochester, Minnesota, United StatesCompleted
Md Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Fred Hutchinson Cancer Research CenterSeattle, Washington, United StatesRecruiting
University of WisconsinMadison, Wisconsin, United StatesRecruiting
Blacktown Cancer and Haematology CentreBlacktown, New South Wales, AustraliaRecruiting
Liverpool HospitalLiverpool, New South Wales, AustraliaRecruiting
Icon Cancer Centre South BrisbaneSouth Brisbane, Queensland, AustraliaRecruiting
Monash HealthClayton, Victoria, AustraliaRecruiting
Cabrini Hospital MalvernMalvern, Victoria, AustraliaRecruiting
The First Affiliated Hospital of Bengbu Medical UniversityBengbu, Anhui, ChinaRecruiting

+ 40 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06625593